Abstract
Diabet. Med. 28, 815–817 (2011) Aims  We evaluated the antibody response to a single‐dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses.Methods  Eighty‐two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti‐haemagglutinin antibody ELISA.Results  Among 70 antibody‐negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1‐specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate.Conclusions  Our data show low cross‐reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger‐scale, case‐controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two‐dose vaccination or have antibody titres measured after the first vaccination.